New anti-emetic product launched

Jan 15, 2018

Dechra Veterinary Products has launched a new formulation anti-emetic injection, Prevomax, for the treatment and prevention of vomiting and nausea in dogs and cats. The manufacturer said it contains benzyl alcohol, a preservative that is known to reduce pain at the injection site, compared to the alternative maropitant injection that is preserved by metacresol. The convenient 20ml bottle has a 56-day broached shelf life, making it ideal, said the firm, for use in a busy practice across multiple patients, reducing wastage. Dechra brand manager Claire Morgan said: “Human clinical studies have shown that an injection containing benzyl alcohol causes less pain than an injection preserved with metacresol. “Prevomax is particularly useful for the treatment and prevention of nausea induced by chemotherapy and for treatment of vomiting, in combination with other supportive measures.” Dechra is inviting veterinary professionals to share their experience of using Prevomax for a chance to win a £100 Amazon gift card. Entries should be submitted via the Dechra website by 28 February. ...

Read More

Vets urged to back #BreedtoBreathe campaign

Jan 8, 2018

The BVA is urging vets to join its new #BreedtoBreathe campaign and help tackle the prevalence of brachycephalic dogs in advertising and social media. The call comes as new figures show almost half of all UK vets (49 per cent) believe their clients who choose brachycephalic dogs are swayed by social media or celebrities. Data from the BVA’s Voice of the Veterinary Profession survey also shows that almost all companion animal vets (98 per cent) treated brachycephalic dogs for conformation-related health problems in the last year. As part of its campaign, BVA is urging practices to avoid using images of brachycephalic breeds across their own communication channels. They are also encouraging practices to write to brands that use brachycephalic breeds in their advertising. To support practices, BVA has developed a position statement, a 10-point plan and an online toolbox. The position statement was approved at BVA’s December council and lists actions that veterinary practices can undertake to improve the health and welfare of brachycephalic breeds. BVA President John Fishwick said:... ...

Read More

Detector puts diagnosis power in clinicians’ hands

Nov 27, 2017

Vets looking to diagnose and monitor anaemia can obtain results in 10 seconds with a new haematocrit/haemoglobin detector from Vet Direct. The AniPoc Handheld Monitor is a portable unit that enables clinicians to conduct a single-step ear prick test to diagnose and monitor anaemia in dogs, cats and horses. Such an approach eliminates the need to spend any time in the lab and, once obtained, the result can be saved for future review, if necessary – the company said. Leon Wright, managing director at Vet Direct, said: “The AniPoc device eliminates the need to draw blood with a syringe – a simple pin prick is enough – and it is perfect for both veterinary practices and home visits. “The speed and accuracy of the product means it is better equipped to monitor animals undergoing anaesthesia or transfusions, and can be used to effectively screen animals taking part in pet blood banks and mobile clinics.” The AniPoc Handheld Monitor and Starter Kit is available from Vet Direct for £250. For more... ...

Read More

New treatment that enhances product choice is ‘spot-on’

Nov 13, 2017

Vets have another tool in their kit to treat fleas and ticks with the release of Bravecto Spot-on for Dogs. MSD Animal Health has added to its existing range with the new product, which offers 12-week flea and tick protection, and provides vets and owners with more choice when it comes to treatment. The complementary product joins the Bravecto Dog Chew and follows swiftly on the heels of the launch of Bravecto Spot-on for Cats. MSD marketing manager Amanda Melvin said: “Our research has shown convenience is the key to improving compliance and successfully eradicating fleas and ticks. “By offering a new formulation of a 12-week treatment, Bravecto Spot-on for Dogs further increases the opportunity. It improves the choice for vets and pet owners, depending on the client’s lifestyle and type of dog.” The product also affords vets the opportunity to raise the topic of fleas and ticks with clients that have been more reluctant to use existing products, Ms Melvin added. A range of materials for practice staff and... ...

Read More

Pimobendan study outcome – a ‘revolution’ for vet cardiology

Nov 13, 2017

A product that delays onset of congestive heart failure (CHF) in dogs by 15 months offers a “paradigm shift” in the way vets diagnose and treat myxomatous mitral valve disease (MMVD). Boehringer Ingelheim, the company behind pimobendan drug Vetmedin, cautiously estimated 7.5% of all dogs would suffer heart disease in their lifetimes, with MMVD its most prevalent form. Vetmedin was already licensed for the treatment of canine CHF from dilated cardiomyopathy or valvular insufficiency, as well as for treatment of cardiomyopathy in the preclinical stage in Dobermann pinschers. However, following the largest clinical trial in veterinary cardiology, the product can now be used by vets to treat the preclinical stage of MMVD, delaying onset of the clinical symptoms of heart failure. At an official launch for the European veterinary press, held in Frankfurt and attended by Veterinary Times, it was noted up to 40 million dogs worldwide could now benefit with treatment from pimobendan. The evaluation of pimobendan in dogs with cardiomegaly (EPIC) study set out to analyse whether long-term... ...

Read More